Autoinjectors Market Forecast up to 2024

  • Product Code:
    RP-ID-10082727
  • Published Date:
    Apr 2019
  • Region:
    Global
  • Pages:
    95
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Autoinjectors Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.
Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.
Market Analysis: The “global autoinjectors market” is estimated to witness a CAGR of 17.1% during the forecast period 2018–2024. The autoinjectors market is analyzed based on three segments – products, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.
Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.
Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.
Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company’s customer base in recent years.
Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:


Table of Contents
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Total Addressable Market 10
2 Report Outline 13
2.1 Report Scope 13
2.2 Report Summary 13
2.3 Research Methodology 14
2.4 Report Assumptions 14
3 Market Snapshot 16
3.1 Market Definition – Infoholic Research 16
3.2 Segmented Addressable Market 16
3.3 Industry Trends 17
3.4 Related Markets 18
3.4.1 Transdermal Drug Delivery 18
3.4.1.1 Trends of cardiovascular drugs market 19
3.4.2 Pulmonary Drug Delivery Systems (PDDS) 19
3.4.3 Insulin Pumps 20
4 Market Outlook 22
4.1 Cost comparison of EpiPen and its Alternatives 22
4.2 Market Segmentation 22
4.3 Porter 5(Five) Forces 23
4.4 PEST Analysis 25
5 Market Characteristics 26
5.1 Market Dynamics 26
5.1.1 Drivers 26
5.1.1.1 Increasing prevalence of Anaphylaxis 26
5.1.1.2 Rising incidence of chronic disease 27
5.1.1.3 Increased Development Biologics / Biosimilars 28
5.1.1.4 Growing demand for home care 28
5.1.2 Opportunities 28
5.1.2.1 Increase in healthcare spending 28
5.1.2.2 Opportunities in emerging market 29
5.1.2.3 Favorable government policies 29
5.1.3 Restraints 30
5.1.3.1 Competition among major vendors 30
5.1.3.2 Increased product recall 30
5.1.3.3 High product pricing 30
5.2 DRO – Impact Analysis 31
5.3 Key Stakeholders 32
6 Application: Market Size and Analysis 33
6.1 Overview 33
6.2 Anaphylaxis 34
6.3 Multiple Sclerosis 35
6.4 Rheumatoid Arthritis 36
6.5 Diabetes 37
6.6 Others 38
7 Product Type: Market Size and Analysis 40
7.1 Overview 40
7.2 Disposable autoinjector 40
7.3 Reusable autoinjectors 41
8 Regions: Market Size and Analysis 43
8.1 Overview 43
8.2 North America 44
8.2.1 Overview 44
8.3 Europe 45
8.3.1 Overview 45
8.4 Asia Pacific 46
8.4.1 Overview 46
8.5 Rest of the World 48
8.5.1 Overview 48
9 Competitive Landscape 49
10 Vendors Profile 51
10.1 Amgen Inc. 51
10.1.1 Overview 51
10.1.2 Geographic Presence 54
10.1.3 Business Focus 55
10.1.4 SWOT Analysis 56
10.1.5 Business Strategies 57
10.2 Becton Dickinson and Company 57
10.2.1 Overview 57
10.2.2 Business Units 60
10.2.3 Geographic Revenue 61
10.2.4 Business Focus 61
10.2.5 SWOT Analysis 61
10.2.6 Business Strategies 62
10.3 Mylan N.V. 62
10.3.1 Overview 62
10.3.2 Business Segments 64
10.3.3 Geographic Presence 66
10.3.4 Business Focus 66
10.3.5 SWOT Analysis 66
10.3.6 Business Strategies 67
10.4 Bayer AG 67
10.4.1 Overview 67
10.4.2 Business Units 69
10.4.3 Geographic Presence 70
10.4.4 Business Focus 71
10.4.5 SWOT Analysis 71
10.4.6 Business Strategies 72
10.5 Eli Lilly & Company Ltd. 72
10.5.1 Overview 72
10.5.2 Business Units 74
10.5.3 Geographic Revenue 75
10.5.4 Business Focus 75
10.5.5 SWOT Analysis 75
10.5.6 Business Strategies 76
10.6 Novartis AG 76
10.6.1 Overview 76
10.6.2 Business Units 80
10.6.3 Geographic Presence 80
10.6.4 Business Focus 81
10.6.5 SWOT Analysis 81
10.6.6 Business Strategies 82
1 Vendors Profile 83
1.1 Ypsomed Holding AG 83
1.1.1 Overview 83
1.2 Biogen Pharmaceuticals 84
1.2.1 Overview 84
1.3 Pfizer Inc. 85
1.3.1 Overview 85
1.3.2 Highlights 87
1.4 Teva Pharmaceutical Industries Ltd. 87
1.4.1 Overview 87
1.5 Antares Pharma, Inc. 89
1.5.1 Overview 89
1.6 Johnson & Johnson 90
1.6.1 Overview 90
1.7 AbbVie Inc. 91
1.7.1 Overview 91
2 Annexure 94
Abbreviations 94

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Mylan NV
Novartis AG
Amgen, Inc.
Becton Dickinson and Company
Bayer AG
Eli Lilly & Company Ltd Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie Inc
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports